[»] Jump to Summary... A growing partnership between Immunai and pharmaceutical giant AstraZeneca is moving into a new phase, with both sides expanding their long-running collaboration in oncology research. The agreement now stretches through 2027 and could see Immunai earn up to $37.5 million across 2026 and 2027, depending on milestones and progress in clinical
Related Articles
Don't miss out on breaking stories and in-depth articles.